PubMed Health⌕ Search

PubMed · 12916101

Coordination algorithms control molecular architecture: [CuI4(L2)4]4+ grid complex versus [MII2(L2)2X4]y+ side-by-side complexes (M=Mn, Co, Ni, Zn; X=solvent or anion) and [FeII(L2)3][Cl3FeIIIOFeIIICl3].

Abstract

The synthesis and characterisation of a pyridazine-containing two-armed grid ligand L2 (prepared from one equivalent of 3,6-diformylpyridazine and two equivalents of p-anisidine) and the resulting transition metal (Zn, Cu, Ni, Co, Fe, Mn) complexes (1-9) are reported. Single-crystal X-ray structure determinations revealed that the copper(I) complex had self-assembled as a [2 x 2] grid, [Cu(I) (4)(L2)(4)][PF(6)](4).(CH(3)CN)(H(2)O)(CH(3)CH(2)OCH(2)CH(3))(0.25) (2.(CH(3)CN)(H(2)O)(CH(3)CH(2)OCH(2)CH(3))(0.25)), whereas the [Zn(2)(L2)(2)(CH(3)CN)(2)(H(2)O)(2)][ClO(4)](4).CH(3)CN (1.CH(3)CN), [Ni(II) (2)(L2)(2)(CH(3)CN)(4)][BF(4)](4).(CH(3)CH(2)OCH(2)CH(3))(0.25) (5 a.(CH(3)CH(2)OCH(2)CH(3))(0.25)) and [Co(II) (2)(L2)(2)(H(2)O)(2)(CH(3)CN)(2)][ClO(4)](4).(H(2)O)(CH(3)CN)(0.5) (6 a.(H(2)O)(CH(3)CN)(0.5)) complexes adopt a side-by-side architecture; iron(II) forms a monometallic cation binding three L2 ligands, [Fe(II)(L2)(3)][Fe(III)Cl(3)OCl(3)Fe(III)].CH(3)CN (7.CH(3)CN). A more soluble salt of the cation of 7, the diamagnetic complex [Fe(II)(L2)(3)][BF(4)](2).2 H(2)O (8), was prepared, as well as two derivatives of 2, [Cu(I) (2)(L2)(2)(NCS)(2)].H(2)O (3) and [Cu(I) (2)(L2)(NCS)(2)] (4). The manganese complex, [Mn(II) (2)(L2)(2)Cl(4)].3 H(2)O (9), was not structurally characterised, but is proposed to adopt a side-by-side architecture. Variable temperature magnetic susceptibility studies yielded small negative J values for the side-by-side complexes: J=-21.6 cm(-1) and g=2.17 for S=1 dinickel(II) complex [Ni(II) (2)(L2)(2)(H(2)O)(4)][BF(4)](4) (5 b) (fraction monomer 0.02); J=-7.6 cm(-1) and g=2.44 for S= 3/2 dicobalt(II) complex [Co(II) (2)(L2)(2)(H(2)O)(4)][ClO(4)](4) (6 b) (fraction monomer 0.02); J=-3.2 cm(-1) and g=1.95 for S= 5/2 dimanganese(II) complex 9 (fraction monomer 0.02). The double salt, mixed valent iron complex 7.H(2)O gave J=-75 cm(-1) and g=1.81 for the S= 5/2 diiron(III) anion (fraction monomer=0.025). These parameters are lower than normal for Fe(III)OFe(III) species because of fitting of superimposed monomer and dimer susceptibilities arising from trace impurities. The iron(II) centre in 7.H(2)O is low spin and hence diamagnetic, a fact confirmed by the preparation and characterisation of the simple diamagnetic iron(II) complex 8. Mössbauer measurements at 77 K confirmed that there are two iron sites in 7.H(2)O, a low-spin iron(II) site and a high-spin diiron(III) site. A full electrochemical investigation was undertaken for complexes 1, 2, 5 b, 6 b and 8 and this showed that multiple redox processes are a feature of all of them.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yanhua Lan, Dietmar K Kennepohl, Boujemaa Moubaraki, Keith S Murray, John D Cashion, Geoffrey B Jameson, Sally Brooker. 2003-08-18. Coordination algorithms control molecular architecture: [CuI4(L2)4]4+ grid complex versus [MII2(L2)2X4]y+ side-by-side complexes (M=Mn, Co, Ni, Zn; X=solvent or anion) and [FeII(L2)3][Cl3FeIIIOFeIIICl3].. https://doi.org/10.1002/chem.200304915

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗